BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAH4. A total of 63 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $333,000 | +2.5% | 310,000 | 0.0% | 0.00% | – |
| Q3 2020 | $325,000 | -97.0% | 310,000 | -96.6% | 0.00% | -100.0% |
| Q2 2020 | $10,999,000 | +949.5% | 9,000,000 | +800.0% | 0.00% | – |
| Q1 2020 | $1,048,000 | -0.8% | 1,000,000 | 0.0% | 0.00% | – |
| Q4 2019 | $1,056,000 | -2.3% | 1,000,000 | -9.1% | 0.00% | – |
| Q3 2019 | $1,081,000 | -38.8% | 1,100,000 | -35.3% | 0.00% | – |
| Q2 2019 | $1,765,000 | +1.3% | 1,700,000 | -0.2% | 0.00% | – |
| Q1 2019 | $1,742,000 | +39.0% | 1,703,000 | +35.2% | 0.00% | – |
| Q4 2018 | $1,253,000 | -87.6% | 1,260,000 | -86.7% | 0.00% | -100.0% |
| Q3 2018 | $10,125,000 | -3.6% | 9,500,000 | -8.7% | 0.00% | 0.0% |
| Q2 2018 | $10,506,000 | -16.2% | 10,400,000 | -22.1% | 0.00% | 0.0% |
| Q1 2018 | $12,532,000 | -19.1% | 13,350,000 | -14.1% | 0.00% | -50.0% |
| Q4 2017 | $15,492,000 | +40.3% | 15,550,000 | +42.7% | 0.00% | +100.0% |
| Q3 2017 | $11,043,000 | – | 10,900,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SHENKMAN CAPITAL MANAGEMENT INC | 30,138,000 | $29,510,000 | 3.72% |
| PFM Health Sciences, LP | 45,910,000 | $46,002,000 | 1.72% |
| Cheyne Capital Management (UK) LLP | 2,320,000 | $2,330,000 | 1.47% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 41,077,000 | $41,277,000 | 0.66% |
| SSI INVESTMENT MANAGEMENT LLC | 9,071,000 | $9,068,000 | 0.50% |
| PALISADE CAPITAL MANAGEMENT, LP | 14,548,000 | $14,612,000 | 0.34% |
| RWC Asset Management LLP | 7,500,000 | $7,552,000 | 0.21% |
| KBC Group NV | 400,000 | $40,316,000 | 0.15% |
| PROSPECTOR PARTNERS LLC | 1,000,000 | $1,000,000 | 0.12% |
| MACKAY SHIELDS LLC | 11,822,000 | $11,816,000 | 0.10% |